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physician, 45% reported interest in an ED treatment, and 72%
believed that physicians should routinely inquire about ED.
CONLCUSIONS: Although most ED patients reported not
speaking with their physician, almost half were interested in
treatment. Patients reported initiating ED discussions more often
than physicians; however, the majority felt that physicians should
routinely ask about sexual function.
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OBJECTIVE: To interview men with BPH to determine their
expectations regarding treatment. Collection of demographic
data, International Prostate Symptom Score (IPSS), bother score,
and patient satisfaction information are standard outcome mea-
sures that provide contextual information for reviewing patient
expectations. METHODS: Multiple individual subject inter-
views were conducted at 4 geographically dispersed sites in the
US. Subjects with diagnosed BPH who met entry were included.
Research subjects completed the IPSS, BPH “bother score”,
general health questionnaires, and provided up to two top expec-
tations from treatment of BPH. Patients were thoroughly
debriefed on their answers to clarify unclear responses.
RESULTS: Thirty-seven subjects who met the criteria were inter-
viewed as part of the qualitative research. The mean age was 66
years [range, 45–82 years] and the mean IPSS score was 20
[range, 7–31]. Subjects reported a mean Bother Score of 3.1.
Thirty-ﬁve subjects (95%) reported a primary expectation for
treatment, and 26 subjects (70%) expressed primary and sec-
ondary expectations from treatment. Thirty-one subjects (89%)
expressed symptom relief as their primary expectation, followed
by reduced, or no side-effects from treatment (9%). Detailed
primary expectations included reduction in abnormal urination
(31%), reduction in frequency (20%), and reduction in nocturia
(17%). Similarly, 88% patients reported symptom relief as their
top secondary expectation. Urine control (35%), reduction in
frequency (15%), lack of sexual side-effects (8%) and reduction
in nocturia (8%) were among the top secondary expectations
from BPH treatment. CONCLUSIONS: This research indicates
that men with BPH primarily expect treatments to relieve symp-
toms. Most symptoms were identical to over-active bladder in
females. The results from this small qualitative research study
will help inform future selection of optimal measurement 
instruments for subjects in clinical trials and in routine clinical
practice.
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OBJECTIVE: To develop a questionnaire that focuses on patient
satisfaction with treatment for BPH symptoms. There are no
current questionnaires that focus on this important patient-
reported outcome. METHODS: Multiple individual subject
interviews (ISI’s) with patients currently or recently receiving
treatment for BPH was conducted to ﬁnalize content for a patient
satisfaction with treatment questionnaire. Patients selected were
required to have a diagnosis of BPH. and an IPSS total score of
greater than or equal to seven. Interviews were conducted using
an initial pool of items developed from previous patient research.
The literature was also utilized to complement item selection.
Open-ended questions about their disease and its impact were
conducted to assess missing content in the questionnaire. Sub-
jects were debriefed thoroughly on satisfaction with content,
vocabulary, and item. RESULTS: Twelve patients were inter-
viewed and a total of 13 questions were developed from this
research. The mean age was 62.3yrs (range 54–72yrs) with
majority being Caucasian males (92%) with various levels of
education. Mean IPSS score was 20.58 (range 14–30). The ﬁnal
questionnaire developed utilized a 5-point Likert scale with some
questions including a 6th option for “does not apply”. The
content of the ﬁnal questionnaire ranged from medication impact
on various symptoms of BPH, including over-active bladder type
symptoms of frequency, urgency, and nocturia. Activity impact
was also signiﬁcant and included impact of medication on ability
to interact more freely in social situations, impact on travel,
activities, and relationships (family and sexual). Cost and side
effects were also issues that concerned many of the subjects and
were included in the ﬁnal questionnaire. CONCLUSIONS: The
13-item ﬁnal questionnaire (BPH-PSTQ) generated after ISIs
with 12 subjects was easily understood by subjects in this qual-
itative development research. The content was also found to be
comprehensive of subjects concerns and major issues.
PIH18
EXPLORATORY FACTOR ANALYSIS OF A 13 ITEM BPH
PATIENT SATISFACTION WITH TREATMENT
QUESTIONNAIRE (BPH-PSTQ)
Barron R
Allergan Corp, Irvine, CA, USA
OBJECTIVES: The factor structure of the BPH-PSTQ was eval-
uated. METHODS: A cross sectional survey was conducted with
BPH subjects that included the BPH-PSTQ. Exploratory factor
analysis was conducted using maximum likelihood estimation
and MINRES. Many criteria were evaluted to assess the number
of factors including scree plots, the number of factors with eigen-
values greater then one, proportion of variance explained by
factors, and various oblique and orthogonal rotations of the
initial unrotated solution. RESULTS: A total of 768 subjects had
complete data for analysis. The initial unrotated solution using
maximum likelihood estimation left two factors with eigenval-
ues greater then one (25.2, 1.7). The variance explained by the
dominant factor in the unrotated solution was 93%. Signiﬁcance
tests suggested that more then two factors were needed based
upon chi-square results. Analysis of scree plot results demon-
strated that there was one dominant factor and possibly a second
factor that could be considered before there was a signicant
plateau on the plot. Quartimax rotation demonstrated a one
factor solution with questions 11 and 13 not loading very highly
on the dominant factor (0.54, 0.53). Final communality estimate
were also not as good for these two items. Other rotations con-
ﬁrmed the misﬁt of item 13. CONCLUSIONS: The unidimen-
sionality of the BPH-PSTQ needs to be further explored to
determine if there are multiple underlying factors with sub-scales
or multiple distinct factors via conﬁrmatory factor analysis mod-
eling. Item 13 was the only item that did not seem to ﬁt with
any of the other items in the scale, and did not load well on any
latent factors.
